Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 100,000 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 100,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at $983,271.96. This represents a 78.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Andrew Dudum also recently made the following trade(s):

• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $41.94 on Wednesday. The stock has a 50-day simple moving average of $29.58 and a 200 day simple moving average of $22.86. Hims & Hers Health, Inc. has a 52-week low of $8.51 and a 52-week high of $41.98. The company has a market cap of $9.16 billion, a PE ratio of 95.32 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the business earned ($0.04) EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HIMS. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Morgan Stanley initiated coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $25.13.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Crewe Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Hims & Hers Health during the fourth quarter worth about $48,000. GAMMA Investing LLC boosted its position in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.